^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etentamig intravenous (ABBV-383 IV)

    i
    Other names: ABBV-383 IV, TNB-383B, TNB 383B
    Associations

    News

    Trials
    Company:
    AbbVie
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    CONQUISTADOR: Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=220, Not yet recruiting, Universitätsklinikum Hamburg-Eppendorf
    New P1/2 trial
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • etentamig intravenous (ABBV-383 IV)
    28d
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Recruiting, AbbVie | Trial primary completion date: Sep 2031 --> Feb 2028
    Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    1m
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie
    Trial initiation date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    2ms
    Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    3ms
    Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=55, Recruiting, AbbVie | Trial completion date: Feb 2027 --> Dec 2027
    Trial completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    3ms
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie
    Trial initiation date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    3ms
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    4ms
    M22-574: A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monotherapy Study) (2023-506668-15-00)
    P2/3, N=147, Active, not recruiting, AbbVie Deutschland GmbH & Co. KG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • etentamig intravenous (ABBV-383 IV)
    4ms
    M25-586: A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (2025-520897-21-00)
    P2/3, N=24, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P2/3 trial • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    4ms
    ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    etentamig intravenous (ABBV-383 IV)
    4ms
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Trial primary completion date: Oct 2041 --> Jan 2042
    Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    5ms
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2042 --> Oct 2041
    Enrollment open • Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)